| # | Berichttitel | Resultaat info | Datum | Gebruiker | Forum |
| Antwoord op: Facial paralysis and psilocybin | 0 Relevantie | 2 maanden geleden | Research | Q&A | |
| Natural Compounds (Psilocybin and Lion’s Mane) in Nerve Repair Psilocybin and Neurotrophic Signaling Psilocybin (from “magic” mushrooms) is converted in vivo to psilocin, a partial agonist at serotonin 5-HT₂A receptors. This serotonergic activation triggers downstream pathways (e.g. mTOR, CREB) associated with neuroplasticity. Notably, psychedelics have been shown to directly bind the BDNF receptor TrkB: LSD and psilocin bind TrkB with very high affinity, enhancing BDNF signaling. In mice, a single dose of psilocybin induced a rapid 10% increase in dendritic spine size and density in frontal cortex within 24h, with effects lasting at least one month. These data indicate fast and enduring synaptic remodeling under psilocybin. By analogy, such BDNF/TrkB-mediated plasticity could support regeneration in injured nerves. Mechanisms: Psilocybin activates 5-HT₂A receptors on cortical glutamatergic neurons, leading to glutamate release and cascade activation (mTOR, ERK/CREB) that upregulates BDNF and related plasticity genes. The 5-HT₂A→mTOR-BDNF pathway overlaps with classic antidepressants. Independently, direct TrkB binding by psilocin also promotes endogenous BDNF signaling. Thus psilocybin triggers neurotrophic cascades (BDNF/TrkB) that enhance neurite growth and synaptogenesis. Evidence (Animal/In Vitro): In rodents, psilocybin rapidly increases excitatory neurotransmission and spine formation in prefrontal neurons. It also reverses stress-induced synaptic deficits in depressed models. In vitro, psychedelics (including DMT/5-MeO-DMT) have been shown to induce neurite outgrowth via TrkB/mTOR. Animal studies of other serotonergic psychedelics report elevated BDNF expression in cortex and hippocampus. No direct studies on facial or peripheral nerve injury and psilocybin were found; however, psilocybin’s broad promotion of plasticity (spine formation, axon sprouting) suggests it could aid regeneration indirectly. Evidence (Human): Formal trials of psilocybin have focused on mood disorders, not nerve repair. In small human case series, microdoses of psilocybin helped relieve chronic neuropathic pain (likely involving peripheral nerve dysfunction). Three patients with refractory neuropathic pain reported robust, sustained pain reduction on low-dose psilocybin. Effects emerged without hallucinations and were enhanced by concurrent exercise, hinting at a plasticity-mediated mechanism. These anecdotal reports suggest psilocybin may support neural recovery or modulation in humans. Lion’s Mane Mushroom (Hericium erinaceus) and Neuroregeneration Lion’s Mane (Hericium erinaceus) is a culinary/medicinal fungus long used in East Asia for neurological health. Its neurotrophic effects derive from compounds called hericenones (fruiting body) and erinacines (mycelium). These low-molecular-weight cyathane diterpenoids cross the blood–brain barrier and stimulate neurotrophin synthesis. In particular, erinacines A–H have been shown to induce nerve growth factor (NGF) expression. For example, erinacine A (from mycelium) is a potent NGF inducer, while erinacine E alleviates neuropathic pain in rodents. Mechanisms (NGF, Other Neurotrophins): Lion’s Mane extracts upregulate NGF production in the central and peripheral nervous system. This promotes survival and outgrowth of cholinergic and sensory neurons. Erinacines/ hericenones activate TrkA signaling (NGF receptor) and also enhance downstream ERK/CREB pathways. Recent research isolated novel erinacine-derived molecules (e.g. NDPIH, hericene A) that strongly promote axon outgrowth and branching in cultured hippocampal neurons. These compounds increased multiple neurotrophins: TrkB inhibition only partially blocked their effect, implying they also engage BDNF-dependent and independent pathways. In vivo, mice fed Lion’s Mane extract (including hericene A) showed elevated neurotrophin expression and signaling in brain, leading to markedly enhanced hippocampal memory. In short, Lion’s Mane appears to act through a pan-neurotrophic mechanism, principally via NGF but also modulating BDNF and other factors. Evidence (Preclinical): Numerous animal and cell studies support nerve-regenerative effects. In rodents, Lion’s Mane (mycelium or extract) improves outcomes in models of neural injury and aging. One study demonstrated that Lion’s Mane polysaccharides promote peripheral nerve regeneration and muscle recovery after injury. In vitro, Lion’s Mane fractions induce neurite extension in PC12 and hippocampal neurons, even in serum-free conditions. These effects correlate with increased NGF and neuritogenic signaling. Cognitive rodent models (e.g. Alzheimer’s, stroke) show improved performance and neural plasticity markers after Lion’s Mane treatment. Evidence (Human): Clinical data are limited but suggest cognitive/mood benefits. A small double-blind study of healthy adults found that a single dose (1.8 g) of Lion’s Mane improved processing speed (Stroop test) and that 28-day supplementation trended toward reduced subjective stress. Another placebo-controlled trial in older adults with mild cognitive impairment (pre-AD) reported cognitive improvements after months of Lion’s Mane consumption (Ng et al., 2009). These findings indicate Lion’s Mane’s neurotrophic action may translate to humans, at least for cognitive function. There are no clinical trials on Lion’s Mane specifically for facial or peripheral nerve injuries, but its safety profile is favorable and its mechanism suggests potential benefit in nerve healing. Synergy: Psilocybin + Lion’s Mane (“Stacking”) Anecdotally, some practitioners “stack” psilocybin microdoses with Lion’s Mane to synergize benefits. Surveys of microdosers report that adding Lion’s Mane is common (39% of respondents). There is no controlled trial of this combination, but theoretical and observational hints exist. Lion’s Mane contains MAO-inhibiting compounds (e.g. erinacines), which might prolong psilocybin’s action (similar to how MAOIs potentiate other psychedelics). Moreover, Lion’s Mane’s NGF-boost could complement psilocybin’s BDNF-boost, jointly enhancing synaptic growth. A recent survey notes that “enhancing properties of Lion’s Mane mushrooms have been proposed to synergize with the ... qualities of psilocybin mushrooms”. However, these claims are speculative. We emphasize that no formal studies have tested psilocybin+Lion’s Mane synergy; any combined use should be approached cautiously. Other Neurotrophins (NT-3, GDNF, etc.) and Natural Modulators Beyond BDNF and NGF, other neurotrophins like neurotrophin-3 (NT-3), glial cell line–derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF) support nerve survival/regrowth. Some natural compounds affect these factors. For example, the Chinese herb Rehmannia glutinosa (used for memory disorders) markedly upregulates GDNF mRNA in astrocytes. Polyphenolic nutraceuticals can also modulate multiple neurotrophins: reviews report that catalpol, resveratrol, curcumin preferentially elevate GDNF (and also BDNF) in neural tissues. Flavonoids generally upregulate BDNF, while non-flavonoid phenols tend to drive GDNF expression. For NT-3 specifically, data are scarcer; however, some herbs and growth factors (e.g. IGF-1, ginsenosides) can increase NT-3 signaling. In sum, natural phytochemicals often activate broad neurotrophic pathways, suggesting that a dietary approach (antioxidant-rich botanicals) may bolster NGF/BDNF/NT-3/GDNF levels to aid nerve repair. Comparative Summary Compound/Category Neurotrophins Enhanced Mechanisms of Action Evidence (Models) Psilocybin ↑ BDNF (via TrkB) (→↑synaptogenesis) 5-HT₂A agonism; direct TrkB binding; mTOR/CREB pathways activated Rodent (dendritic spine growth);Case reports (chronic neuropathic pain). No direct human trials for nerve repair. Lion’s Mane (H. erinaceus) ↑ NGF (release induction);↑ BDNF (indirect);↑ other neurotrophins (pan-NGF/BDNF effect) Hericenones/erinacines cross BBB, stimulate NGF-TrkA signaling and ERK/CREB; NDPIH/Hericene A activate BDNF-linked TrkB and alternative ERK pathways In vitro: neurite outgrowth in neurons;Rodent: improved cognition, nerve repair;Human: small cognitive trials (↑processing speed, mood) Polyphenols (e.g. resveratrol, curcumin, catalpol) ↑ GDNF (and ↑ BDNF) Antioxidant/anti-inflammatory, modulating CREB/ERK; Sirtuin pathways Animal neurodegeneration and regeneration models (↑GDNF/BDNF) Table: Summary of neurotrophic effects, key mechanisms, and evidence level for psilocybin, Lion’s Mane mushroom, and representative phytochemicals. Each of these natural compounds triggers growth-factor pathways: psilocybin mainly via BDNF/TrkB, Lion’s Mane via NGF (and collateral BDNF), and polyphenols via GDNF/BDNF. Animal studies are strong for spine and neurite growth, while human trials are nascent (mostly cognitive endpoints). Conclusion: Psilocybin and Lion’s Mane are promising natural neurotrophic agents. Psilocybin rapidly boosts BDNF-related plasticity, and Lion’s Mane robustly induces NGF (with broader neurotrophin effects). Both have experimental support in neural repair models. Combining them is hypothesized to amplify healing, though clinical data are lacking. Other botanicals (curcumin, resveratrol, Rehmannia, etc.) can further augment GDNF/NT-3 pathways. In sum, a natural, neurotrophin-focused strategy—leveraging mushrooms and phytochemicals to elevate NGF/BDNF/GDNF/NT-3—offers a complementary approach to peripheral and facial nerve healing. | |||||
| Antwoord op: Parkinson's disease and psilocybin - Microdose or macrodose? | 0 Relevantie | 2 maanden geleden | Research | Q&A | |
| ... of non-motor symptoms (mood disturbances, cognitive changes, sleep issues). Traditional treatments (like levodopa and other medications) help manage symptoms but do not stop disease progression. Moreover, many PD patients suffer from depression and anxiety that often precede or accompany the motor decline. These mood symptoms not only reduce quality of life but are linked to faster physical deterioration in PD. This has spurred interest in therapies that can address both neurological and psychological aspects of PD. Psilocybin, the active compound in “magi ... | |||||
| Antwoord op: Sterkste 5-ht2a agonist psychedelica | 0 Relevantie | 4 maanden geleden | marcel | Q&A | |
| De sterkste 5-HT₂A-agonist onder de psychedelische stoffen is 25I-NBOMe. Deze stof heeft een bijzonder lage Ki-waarde van 0,044 nM, wat wijst op een zeer sterke affiniteit voor de 5-HT₂A receptor. Dit maakt 25I-NBOMe tot een van de krachtigste bekende agonisten voor deze receptor in vergelijking met andere psychedelische stoffen. Onderstaande is een tabel pop basis van de 5-HT2A affiniteit van sterkste naar minst sterke agonist (lager getal=meer affiniteit) Stof 5-HT₂A Ki (nM) Opmerkingen 25I-NBOMe 0,044 Potente synthetische hallucinogeen 25CN-NBOH 0,088 Selectieve 5-HT₂A-agonist (S,S)-DMBMPP 2,5 Structuurafgeleide van 25B-NBOMe LSD 2,9 Klassiek psychedelisch middel Psilocine 6,0 Actieve metaboliet van psilocybine 4-HO-MET 13,0 Synthetische tryptamine 5-meo-dmt 15–620 Variabele affiniteit afhankelijk van de studie DMT 127–1.200 Hoofdbestanddeel van ayahuasca Serotonine 6.500 Endogene neurotransmitter | |||||
| Psychedelische therapie en truffelceremonie in relatie tot nieuwe onderwerpen | 0 Relevantie | 4 maanden geleden | marcel | Recente nieuwsberichten | |
| ... varianten zoals magic truffels ingezet om mensen te helpen hun mentale en spirituele blokkades te doorbreken, trauma’s te verwerken en een diepere verbinding met zichzelf en de wereld om hen heen te ontwikkelen. In dit artikel onderzoeken we niet alleen de werkzame stoffen en hun effecten, maar ook de holistische aanpak die nodig is om deze ervaringen veilig en effectief te integreren in het dagelijks leven. We nemen je mee op een reis door de wereld van psychedelica. Van de biochemische werking van psilocybine en psilocine in magic truffels tot de diepe s ... | |||||
| Antwoord op: Gelukshormonen | 0 Relevantie | 5 maanden geleden | Research | Q&A | |
| Het snijvlak tussen gelukshormonen en psychedelica vormt een fascinerend onderzoeksgebied binnen de neurofarmacologie. Uit recent onderzoek blijkt dat zowel endogene gelukshormonen als exogene psychedelische stoffen complexe interacties aangaan met een breed spectrum van neurotransmitterreceptoren, waarbij vooral de serotoninereceptoren (met name 5-HT2A), dopaminereceptoren (D1 en D2), en NMDA-receptoren een centrale rol spelen. Psychedelica zoals psilocybine en LSD vertonen opvallende parallellen met natuurlijke neurotransmitters door hun vermogen om specifieke receptorpopulaties te moduleren, wat resulteert in zowel acute psychoactieve effecten als langdurige neuroplastische veranderingen. De mate van receptorstimulatie varieert aanzienlijk tussen verschillende stoffen – waar klassieke tryptamines zoals DMT een hoge affiniteit voor 5-HT2A-receptoren vertonen, blijken arylcyclohexylaminen zoals ketamine juist sterke NMDA-receptorantagonisten te zijn. Deze receptor-specifieke effecten bieden waardevolle inzichten voor de ontwikkeling van nieuwe therapieën voor stemmingsstoornissen. Neurobiologische Basis van Gelukshormonen Definitie en Functie van Belangrijke Neurotransmitters Gelukshormonen, beter bekend als neurotransmitters en neuropeptides geassocieerd met positieve affectieve toestanden, omvatten een complex netwerk van serotonine, dopamine, endorfinen, oxytocine, GABA, en glutamaat. Serotonine (5-hydroxytryptamine) moduleert stemming, cognitie en perceptie via zeven verschillende receptorfamilies (5-HT1 tot 5-HT7). Dopamine, voornamelijk betrokken bij beloningsverwerking en motivatie, oefent zijn werking uit via vijf dopaminereceptoren (D1-D5). Endorfinen, endogene opioïde peptiden, interageren voornamelijk met μ-opioïde receptoren (MOR) en zijn cruciaal voor pijnmodulatie en euforische ervaringen. Fysiologische Rol van Receptorpopulaties Elke receptorfamilie vertoont unieke distributiepatronen en signaaltransductiemechanismen. De 5-HT2A-receptor, dicht opeengepakt in corticale lagen V en VI, activeert het fosfolipase C-signaalpad via Gq-eiwitkoppeling. Dopamine D2-receptoren, overheersend in het striatum, remmen adenylaatcyclase via Gi/o-koppeling. NMDA-receptoren functioneren als ligand-gated ionkanalen die calciuminflux mogelijk maken, essentieel voor synaptische plasticiteit en leerprocessen. Receptor-specifieke Analyse van Psychedelische Stoffen Serotoninereceptoren (5-HT) 5-HT2A Agonisme Klassieke psychedelica vertonen affiniteit voor 5-HT2A-receptoren: LSD: Partiële agonist (EC50 ≈ 3 nM, Emax ≈ 70% van serotonine) Psilocybine/Psilocine: Volledige agonist (EC50 ≈ 6 nM, Emax ≈ 95%) DMT: Volledige agonist (EC50 ≈ 12 nM, Emax ≈ 100%) Mescaline: Matige agonist (EC50 ≈ 150 nM, Emax ≈ 80%) 5-HT1A Activering Verschillende psychedelica moduleren tevens 5-HT1A-autoreceptoren: Psilocine: Partiële agonist (Ki ≈ 8 nM) LSD: Volle agonist (Ki ≈ 1 nM) 5-meo-dmt: Selectieve agonist (Ki < 0.5 nM) Dopaminerge Receptoren D2 Receptor Affiniteit LSD: Matige agonist (Ki ≈ 50 nM) MDMA: Indirecte activatie via dopamineheropnameremming 2C-B: Milde D2-affiniteit (Ki ≈ 400 nM) NMDA Receptor Antagonisme Ketamine: Non-competitieve antagonist (IC50 ≈ 0.5 μM) PCP: Sterke antagonist (IC50 ≈ 0.1 μM) DXM: Zwakkere antagonist (IC50 ≈ 10 μM) GABAerg Systeem Interacties Muscimol (Amanita muscaria): Selectieve GABA-A agonist (EC50 ≈ 1 μM) THIP: Synthetische GABA-A agonist (EC50 ≈ 0.3 μM) Glutamaat Modulatie Psychedelica beïnvloeden glutamaterge transmissie via indirecte mechanismen: Psilocybine: Verhoogt prefrontale glutamaat via 5-HT2A-gemedieerde disinhibitie Ketamine: Blokkeert NMDA-receptoren → AMPA-receptor upregulatie | |||||
| MET BETREKKING TOT: RE: Bufo Alvarius ceremonie | 0 Relevantie | 7 maanden geleden | marcel | Q&A | |
| ... stof 5-meo-dmt en daarnaast ook andere verbindingen, zoals bufotenine (5-HO-DMT), bufagin en bufotenidine. Deze stoffen hebben ook psychoactieve eigenschappen, maar zijn minder van invloed op de uitwerking van Bufo. Wij gebruiken geen Bufo en het vermijden van het gebruik van Bufo is diervriendelijker om verschillende redenen: Leefgebied verstoring: Het oogsten van de afscheidingen van de Colorado River Toad (Bufo alvarius) kan hun natuurlijke leefgebied verstoren. Deze padden worden vaak gevangen, wat stress en mogelijke schade aan hun omgeving veroorz ... | |||||